Fangsheng Pharmaceuticals decided to buy a 51% stake in Sanhua Pharmaceuticals for $10.2 million

On July 16, Hunan Fangsheng Pharmaceutical Co., Ltd. announced that, in order to further enhance the company's overall competitiveness and speed up the industrial layout, it was decided to transfer its own capital of 10.2 million yuan to the company's 51% stake in Sanhua Pharmaceuticals.
It is understood that Sanhua Pharmaceutical's existing state-approved drug production registration number 7, with 2 registered trademarks, its facilities, equipment trial production and production has been fully equipped with production capacity, the first phase of the project production capacity for the annual output of Sanhua bone scattered 70 million bags, 200 million tablets of simitidine tablets. Sanhua Pharmaceuticals existing dispersants and tablets two dosage line, which to dispersal agent "three flower bone dispersion" as the main product.
flower bone scattered from the ancient side, has thousands of years of history. Sanhua bone dispersion has experienced a thousand years of clinical application, proved that there is a better effect, for the Chinese medicine in the "classic test." The product can quickly stimulate the bone injury "bone bone" generation, shorten the time of bone injury treatment, improve the prognosiosal effect.
Osteoporosis can be divided into fractures, lower back and leg pain, osteoarthritis, anthrax, fall injury, osteoporosis and other diseases, orthopaedic products are divided into stoic injury medication, osteoporosis medication, orthopaedic analgesic medication, osteoarthritis medication, rheumatoid disease medication and other orthopaedic drugs, among which, to stoic injury medication, osteoarthritis medication, rheumatoid medication.
2010-2014, China's orthopaedic painkiller oral Chinese medicine market showed a steady growth trend, the market size increased from 957 million yuan to 1.824 billion yuan, a compound annual growth rate of 17.05 percent. Fractures are common in children and the elderly, with the aging of China's population, fracture drug-related market segment development potential is greater.
Fangsheng Pharmaceuticals said that the company intends to obtain a controlling stake in Sanhua Pharmaceuticals through the transfer of equity, is conducive to further enrich the tablet, dispersant dosage form product category, improve comprehensive competitiveness, accelerate the realization of the company's development strategy. (Sina Medical News)